NASDAQ:MEIP - MEI Pharma Stock Price, Forecast & News

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

MEI Pharma Inc (NASDAQ:MEIP) announced its quarterly earnings results on Thursday, February, 6th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.11. The business had revenue of $1.01 million for the quarter, compared to analysts' expectations of $1.24 million. MEI Pharma had a negative return on equity of 70.99% and a negative net margin of 825.55%. View MEI Pharma's Earnings History.

MEI Pharma is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for MEI Pharma.

2 brokerages have issued 1-year price objectives for MEI Pharma's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate MEI Pharma's share price to reach $10.00 in the next year. This suggests a possible upside of 321.9% from the stock's current price. View Analyst Price Targets for MEI Pharma.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.

Press coverage about MEIP stock has been trending somewhat negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MEI Pharma earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for MEI Pharma.

MEI Pharma saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 367,900 shares, an increase of 25.2% from the December 31st total of 293,800 shares. Based on an average daily trading volume, of 419,200 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.6% of the company's stock are short sold. View MEI Pharma's Current Options Chain.

Some companies that are related to MEI Pharma include Phathom Pharmaceuticals (PHAT), Achillion Pharmaceuticals (ACHN), Radius Health (RDUS), Cytokinetics (CYTK), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Applied Therapeutics (APLT), Endonovo Therapeutics (ENDV), ImmunoGen (IMGN), Homology Medicines (FIXX), Rhythm Pharmaceuticals (RYTM), Dova Pharmaceuticals (DOVA), Collegium Pharmaceutical (COLL), CannTrust (CNTTF) and ANI Pharmaceuticals (ANIP).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Opko Health (OPK), Actinium Pharmaceuticals (ATNM), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL) and Geron (GERN).

MEI Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (8.38%), BVF Inc. IL (5.04%), Renaissance Technologies LLC (2.82%), State Street Corp (1.17%), Point72 Asset Management L.P. (0.80%) and Geode Capital Management LLC (0.74%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, David M Urso and Thomas C Reynolds. View Institutional Ownership Trends for MEI Pharma.

MEIP stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, New York State Common Retirement Fund and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for MEI Pharma.

MEIP stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, NEA Management Company LLC, Point72 Asset Management L.P., Geode Capital Management LLC, Renaissance Technologies LLC, Panagora Asset Management Inc., State Street Corp and DAVENPORT & Co LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold and Thomas C Reynolds. View Insider Buying and Selling for MEI Pharma.

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEIP stock can currently be purchased for approximately $2.37.

MEI Pharma has a market capitalization of $251.22 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.

The official website for MEI Pharma is http://www.meipharma.com/.

MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]